Last updated: July 28, 2026
Omnipaque 350 (iohexol) clinical trials update, market analysis and forecast: volume, pricing, and patent-driven entry risks
Executive summary: Omnipaque 350 (iohexol 350 mg I/mL), an iodinated contrast agent (ICA) for CT and angiography, faces ongoing pressure from lower-cost generic iohexol and competitive brand ICAs. The near-term market is shaped less by exclusive clinical differentiation and more by (1) substitutability and hospital formularies, (2) supply reliability, (3) tender pricing, and (4) route-specific labeling and pack-size economics. Patent exposure for iohexol “brand” products is largely stale in most markets, so the forecast is driven primarily by generic penetration rather than new exclusivity.
Core sizing and outlook (directional): Omnipaque 350 is expected to remain in decline or plateau in mature markets, with growth concentrated in emerging markets where imaging volumes expand faster than contract pricing. Key risk to forecasts is continued downward price pressure from generic ICA erosion, plus potential product discontinuations or manufacturing changes that can cause temporary supply-driven pricing swings.
What is Omnipaque 350 (iohexol 350 mg I/mL) used for and what labels matter for volume?
Omnipaque 350 is an iodinated, water-soluble, nonionic contrast medium containing iohexol at 350 mg I/mL. It is used for contrast-enhanced imaging where iodine density is selected to support adequate attenuation in CT and related angiographic applications.
Which clinical indications drive ordering behavior?
Hospital ordering is primarily influenced by:
- CT contrast use in adult and pediatric populations (protocol-driven dosing).
- Angiography workflows where iodine concentration and viscosity affect injection parameters.
- Compatibility with power injectors, tubing sets, and existing institutional protocols.
What operational factors determine market share more than clinical trial outcomes?
For ICAs, trial signal rarely changes adoption after routine safety and performance benchmarks are met. Adoption is instead governed by:
- Tender price and rebate terms.
- Stock availability and lead times.
- Tender bundling with other contrast products.
- Brand switching friction (system compatibility, staff familiarity, pack-size).
What clinical trials have updated evidence for Omnipaque 350 (iohexol) in the last few years?
Answer (high-level): Clinical trial activity for iohexol products is dominated by comparative safety/quality studies and workflow studies rather than brand-new endpoints that would materially alter label scope. Evidence that changes practice tends to be about imaging protocols (timing, dose optimization, injection rates) and comparative performance between competing ICAs and/or settings (e.g., renal impairment subsets).
Typical trial categories relevant to Omnipaque 350
- Comparative tolerability studies between iohexol and other nonionic ICAs (head-to-head adverse event profiles).
- Dose-ranging or protocol optimization studies for CT angiography and emergency imaging.
- Special populations studies (contrast-associated acute kidney injury risk stratification, pediatric imaging protocols, and hypersensitivity management pathways).
- Real-world evidence cohorts where registries evaluate adverse reactions, contrast leakage, or workflow efficiency.
How to interpret trial updates for commercialization
Even when new studies are published, Omnipaque 350 adoption is usually constrained by:
- Generic availability (same active pharmaceutical ingredient).
- Physician familiarity and institutional contracts.
- Labeling granularity (packaging and concentration switching, not only clinical indication).
Because Omnipaque 350 is an established product, any incremental evidence typically supports continued use rather than driving net new share against cheaper generics.
What is the Orange Book status of Omnipaque 350 (iohexol) and how does exclusivity end?
Answer: Omnipaque 350 is not expected to enjoy meaningful, active patent exclusivity that prevents generic iohexol in most major markets. Generics for iohexol concentrations (including 350 mg I/mL) have been available for years in the U.S., and hospital contracting generally reflects that.
What exclusivity typically exists for contrast agents like iohexol?
For established small molecules, key exclusivity sources (new chemical entity exclusivity, pediatric exclusivity, etc.) are generally long expired. Remaining constraints are usually:
- Late-expiring formulation or packaging patents, where they exist.
- Manufacturing process patents (rare in practice for driving brand exclusivity after widespread generic launches).
- Regulatory exclusivity tied to route, concentration, or labeling updates, if any, which is uncommon for mature ICAs.
When do relevant patents for Omnipaque 350 (iohexol) expire, and what entry barriers remain?
Answer: For iohexol, brand-specific patent estates have largely expired in mature jurisdictions. Generic entry barriers are therefore primarily regulatory and manufacturing quality systems, not long exclusivity timelines.
What patent types historically protected Omnipaque products?
When ICAs have patent protection, it usually covers:
- Specific salt/compound forms (not applicable here because iohexol is the drug substance).
- Formulations, concentration-specific compositions, or stabilizer systems.
- Packaging components and container closure systems.
- Processes for sterilization and manufacturing controls.
In a mature generic environment, these protections generally reduce to narrow, product- and process-specific claims with limited practical leverage.
What matters for litigation leverage in Omnipaque 350
Because many generic iohexol products have already launched, the most relevant question is not “does the brand have a next patent to block,” but “are there remaining packaging or manufacturing process claims that could support enforcement in a specific jurisdiction.”
Which companies sell competing iohexol 350 mg I/mL products and how does Omnipaque compare?
Answer: Competitive pressure comes from multiple generic manufacturers of iohexol 350 mg I/mL and from other nonionic iodinated contrast agents sold under alternative active ingredients. Market share is typically driven by tender pricing and supply reliability.
Direct competition by active ingredient
- Competing brands and generics containing iohexol (same 350 mg I/mL concentration).
- Alternative nonionic ICAs (different iodine concentrations and viscosities) used depending on protocol and injector systems.
Brand vs generic economics
- Generics typically price materially below branded Omnipaque.
- Formularies often require price-comparative equivalence unless a clinical protocol mandates a specific viscosity or workflow attribute.
What generic entry risks exist for Omnipaque 350 (iohexol) from Paragraph IV challenges?
Answer: The primary risk for Omnipaque 350 is not novel Paragraph IV entry, but incremental capture by additional generic entrants through ongoing ANDA approvals and tender contracting. When generics already exist, Paragraph IV leverage is less decisive than procurement decisions.
How to frame “entry risk” in ICAs
In mature ICA categories, “generic entry risk” is usually realized via:
- New generic lots and alternate suppliers.
- Contracting updates at hospital systems.
- Tender re-bids that reprice the formulary.
What is the market outlook for Omnipaque 350: volume, price trends, and revenue projection?
Answer: The outlook is shaped by:
- Imaging volume growth (CT utilization growth supports incremental demand).
- Price deflation from generic substitution (limits revenue growth).
- Switching cycles and tender pricing (quarterly/annual procurement dynamics).
Forecast logic used for mature contrast agents
- Demand: increases with imaging procedures.
- Unit pricing: decreases with generic penetration and procurement leverage.
- Mix: concentration choice (e.g., 300 vs 320 vs 350) and pack sizes change with protocols.
- Retention: brand retention depends on contracts, supply reliability, and institutional preferences.
Market drivers that can temporarily lift branded pricing
- Supply disruptions in any major generic manufacturer.
- Container or manufacturing constraints that limit availability.
- Emergency procurement where hospitals prioritize guaranteed delivery.
These are episodic factors, not structural brand advantages.
How do supply, manufacturing changes, and shortages impact Omnipaque 350 pricing and distribution?
Answer: ICAs are vulnerable to manufacturing capacity shifts and container closure or sterilization constraints. When supply tightens, branded products can hold price better temporarily, but substitution constraints usually reassert once supply normalizes.
What supply events typically do
- Increase acquisition lead times.
- Cause temporary price spikes across the category.
- Trigger emergency purchasing approvals and alternate supplier stocking.
What supply events do not do
- Usually prevent medium-term generic re-contracting once supply normalizes.
How does Omnipaque 350 compare with other iodinated contrast agents (effect on adoption)?
Answer: Adoption between nonionic ICAs is usually protocol- and viscosity-driven. If an alternative product offers similar iodine concentration with lower viscosity, ease of injection, or more favorable tender pricing, substitution tends to follow.
Key comparative dimensions
- Viscosity and injectability at 37°C (protocol fit).
- Adverse reaction rates and hypersensitivity profiles (generally comparable across nonionic ICAs).
- Renal safety pathways and institutional kidney injury prevention protocols (often implemented as standardized care bundles rather than product-specific differences).
What regulatory actions and labeling changes could affect Omnipaque 350 utilization?
Answer: For established ICAs, meaningful regulatory changes are less frequent than in novel therapeutics. Label updates, if any, tend to be incremental and tied to:
- Safety reporting updates.
- Pediatric dosing language refinements.
- Hypersensitivity management language changes.
- Manufacturing or packaging updates.
FDA status dynamics that matter commercially
- Continuity of supply under current manufacturing site approvals.
- Any safety-related communications that affect prescriber behavior.
- Updates to warnings that alter precautionary screening or hydration protocol adherence.
Clinical trial and market timeline: what to watch next for Omnipaque 350
Near-term watchlist (commercially relevant):
- Imaging utilization trends (CT volumes by geography).
- Hospital tender cycles and formulary updates for iohexol 350 mg I/mL.
- Generic price landscape shifts based on new approvals or capacity changes.
- Any safety communications affecting switching behavior in ICAs.
Key Takeaways
- Omnipaque 350 is an established iohexol iodinated contrast product; brand differentiation is limited in a mature, generics-rich category.
- Clinical trial updates typically support continued use rather than materially shifting adoption against lower-cost iohexol generics.
- Market growth is primarily driven by CT imaging volume expansion; branded revenue is capped by generic-driven price deflation.
- Forecast outcomes depend more on contracting, tender pricing, and supply continuity than on exclusivity timelines or new clinical differentiation.
FAQs
- Does Omnipaque 350 have ongoing FDA exclusivity or new-use exclusivity that blocks generic iohexol 350?
- How do hospitals decide between iohexol 350 mg I/mL products during annual contrast tenders?
- Which clinical outcomes in contrast agent trials most influence formulary committee decisions (rate of adverse reactions vs renal protocols)?
- What supply constraints most often cause temporary branded price increases in iodinated contrast agents?
- How does switching between iodine concentrations (e.g., 300 vs 350 mg I/mL) affect injection workflow and adoption?
References (APA)
- FDA (Orange Book) database. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA labeling repository (Drugs@FDA). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- European Medicines Agency product information for iohexol-containing contrast media. https://www.ema.europa.eu/
